Nomura: SINOPHARM (01099) 2024 earnings did not meet expectations, lowering the Target Price to HKD 23.4.

The bank believes that SINOPHARM's earnings fell short of expectations mainly due to the goodwill impairment provision of Guoda Pharmacy.

Zhitong FinanceMar 25 11:09 · Ratings

China National Accord Medicines Corporation (000028): Goodwill impairment causes short-term pressure, but operations are expected to improve by 2025.

Event: The company released the 2024 performance report, during the reporting period the company achieved revenue of 74.378 billion yuan, a year-on-year decrease of 1.5%; net income attributable to shareholders of the listed company was 0.642 billion yuan, a year-on-year decrease of 59.8%, profit.

Southwest SecuritiesMar 20 00:00

China National Accord Medicines' 2024 Profit Plunges 60%

MT NewswiresMar 18 17:14

Sinopharm is consistent: 2024 annual results report

SZSIMar 18 00:00 · Announcements

In 2022, China National Accord Medicines Corporation (01099.HK) earned 0.642 billion RMB, a decline of 59.8%.

SINOPHARM (01099.HK) announced that its subsidiary China National Accord Medicines Corporation (000028.SZ) reported an operating revenue of 74.378 billion RMB for the fiscal year 2024, a decrease of 1.5% year-on-year. The net profit attributable to shareholders was 0.642 billion yuan, a decline of 59.8%, with an EPS of 1.15 yuan. During the year, China National Accord Medicines Corporation recognized an impairment loss of 0.97 billion yuan for intangible assets formed from goodwill and acquisition consideration, reducing the net profit attributable to shareholders by 0.561 billion yuan.

AASTOCKSMar 17 23:55

It is proposed to set aside a goodwill impairment provision of nearly 0.9 billion yuan. China National Accord Medicines Corporation's revenue and net profit are expected to decline in 2024 | Quick Announcement.

① Due to the combined impact of intensified market competition and other factors, China National Accord Medicines Corporation expects a decline in both revenue and Net income for 2024. ② The company plans to make an impairment provision totaling 1.094 billion yuan for credit impairment losses and asset impairment losses.

cls.cnMar 17 22:13